Crossmark

Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?

Published Online: 2016-05-11

Published Print: 2016-09

Authors

Tankó, László B.

Goldhahn, Jörg

Varela, Aurore

Lesage, Elisabeth

Smith, Susan Y.

Pilling, Andrew

Chivers, Simon
Funding

Funding for this research was provided by:

Novartis Pharma AG, Basel, Switzerland
License Information

Text and Data Mining valid from 2016-05-11

Document is current